Pharmafile Logo

How the WHO hepatitis strategy measures up in the field

With hepatitis cases on the rise, Dr Anthony Martinez, member of the International Hepatitis Education Program (IHEP), shares his perspective on the World Health Organization’s new strategy for hepatitis elimination by 2030 and reveals his dynamic and novel colocalization method designed to meet patients where they are.

- PMLiVE

According to the World Health Organization (WHO), approximately 296 million people globally live with hepatitis B, with most unaware of their infection. Africa is the worst impacted region for hepatitis B with a prevalence of 7.5 percent compared to 0.5 percent in the Americas. Hepatitis C impacts an estimated 58 million people across the globe. Again, Africa is the worst-impacted region with a prevalence of 0.8 percent while the Americas see a prevalence of 0.5 percent.

Hepatitis C is a curable disease with patients prescribed an eight-to-12-week oral therapy regimen with cure rates exceeding 95%. Prognosis is not as promising for hepatitis B patients, but there are antiviral drugs available to help combat the virus and limit liver damage. There is hope among researchers and drug developers that hepatitis C treatment innovations can be leveraged to find a cure for hepatitis B. Despite the availability of treatment options to manage hepatitis B and cure hepatitis C, people across the globe are dying from both diseases.

Hepatitis B and C tend to have a higher prevalence among young people, people who inject drugs, people experiencing homelessness, incarcerated individuals, and migrants. Indeed, one of the main barriers to treating these diseases is that a high proportion of patients are part of marginalized groups that are difficult to reach through traditional healthcare systems. This may be due to lack of access or problems preventing patients from visiting doctors such as mistrust of healthcare systems or mental health issues.

In June 2022, the World Health Organization (WHO) released a new strategy for ending the hepatitis B and C epidemics. The strategy focuses on five core areas: delivering high-quality, evidence-based, people-centered services; optimizing systems, sectors, and partnerships for impact; generating and using data to drive decisions for action; engaging empowered communities and civil society; and fostering innovations for impact.

Dr. Anthony Martinez (Tony), a member of the International Hepatitis Education Program (IHEP), has worked in this field for 18 years. He is currently the Medical Director of Hepatology at Erie County Medical Center in Buffalo, New York, and has dedicated his career to caring for patients with addiction disorders. Tony reveals details about his novel colocalization methods and his views on the WHO strategy and how it aligns with what’s realistically possible from the patient and healthcare providers’ perspectives, as well as what pharma companies can do to help.

DOWNLOAD THE FULL ARTICLE HERE

This content was provided by Avalere Health

Company Details

 Latest Content from  Avalere Health 

The desire for connected customer experiences unites stakeholders

Milo Elmir, Managing Consultant, examines the trends changing the behaviors of 3 healthcare stakeholders—patients, payers, and healthcare professionals—and explores how building human-centered solutions will help biopharmaceutical and medical technology companies...

6 critical success factors for flawless execution of a rapid first commercial launch

Annemarie Armstrong, Executive Vice President, US Head of Client Services, shares the key considerations for launching a first commercial product, particularly on a rapid timeline.

How to innovate and influence people in times of misinformation

The pandemic has shown that public trust in promising new medical technologies is far from a given. Senior Writer Tom Vandyck at StoneArch, a member of Fishawack delves into the...

Fishawack Health welcomes expert-led dermatology initiative FIDE to its group

Fishawack Health welcomes FIDE, an independent organization providing its clients with insight from clinical key opinion leaders in inflammatory dermatology

Rethinking immunodermatology: Patient and market insights from leading KOLs and life science leaders

In our new publication, we speak to key opinion leaders and industry experts to uncover novel strategies for commercializing immunodermatology therapies in a crowded market landscape.

How we’re empowering our teams to fight healthcare inequality

Welcoming Sheena Amin-Liebman as our new Diversity and Inclusion Director. Sheena will play a vital role in creating an inspiring environment that empowers staff to better guide its clients in...

Accelerating HTA and payer submissions: how digital connectivity is driving faster patient access

Sotiria Papanicolaou, Chief Consulting Officer at PRMA Consulting, a member of Fishawack Health, explains how the combination of digital innovation and expert insight are removing roadblocks and speeding up the...

Future focus: 3 tools for launching fast in the face of uncertainty

Dan Twibell, Head of Commercial Strategy, Consulting at Fishawack Health, reveals 3 fundamental tools for lean biotechs approaching a rapid launch. He gives his advice on how to manage resources...

Fishawack Health appoints new CEO, Jonathan Koch

Koch will draw on his exceptional experience leading global, customer-centered organizations of scale to build a sustainable future for Fishawack Health.

Fishawack Health appoints Elizabeth Landon in the newly created Chief People Officer role

Elizabeth Landon brings exceptional leadership from a career supporting and scaling people-based businesses in the professional services and non-profit sectors.